Palmidrol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Palmidrol
Accession Number
DB14043
Description

A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

Type
Small Molecule
Groups
Experimental, Nutraceutical
Structure
Thumb
Weight
Average: 299.4919
Monoisotopic: 299.282429433
Chemical Formula
C18H37NO2
Synonyms
  • Hydroxyethylpalmitamide
  • Monoethanolamine palmitic acid amide
  • N-(2-Hydroxyethyl)palmitamide
  • N-hexadecanoylethanolamine
  • N-palmitoylethanolamine
  • Palmidrol
  • palmidrolum
  • Palmitamide MEA
  • Palmitic acid monoethanolamide
  • Palmitinsaeure-beta-hydroxyethylamid
  • Palmitoyl ethanolamide
  • Palmitoyl-EA
  • Palmitoylethanolamide

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetophenazine.
AclidiniumThe risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Palmidrol.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Palmidrol.
AgomelatineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alimemazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Palmidrol is combined with Almotriptan.
AlosetronThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alosetron.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Palmdrol prodes

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as carboximidic acids. These are organic acids with the general formula RC(=N)-OH (R=H, organic group).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboximidic acids and derivatives
Sub Class
Carboximidic acids
Direct Parent
Carboximidic acids
Alternative Parents
Propargyl-type 1,3-dipolar organic compounds / Alkanolamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic acyclic compound / Alkanolamine / Carboximidic acid / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
N-(long-chain-acyl)ethanolamine, endocannabinoid, N-(saturated fatty acyl)ethanolamine (CHEBI:71464) / N-acyl ethanolamines (endocannabinoids) (LMFA08040013)

Chemical Identifiers

UNII
6R8T1UDM3V
CAS number
544-31-0
InChI Key
HXYVTAGFYLMHSO-UHFFFAOYSA-N
InChI
InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
IUPAC Name
N-(2-hydroxyethyl)hexadecanamide
SMILES
CCCCCCCCCCCCCCCC(=O)NCCO

References

General References
Not Available
Human Metabolome Database
HMDB0002100
KEGG Drug
D08328
KEGG Compound
C16512
ChemSpider
4509
BindingDB
29083
RxNav
2001986
ChEBI
71464
ChEMBL
CHEMBL417675
ZINC
ZINC000008035017
Wikipedia
Palmitoylethanolamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPain, Chronic1
2CompletedTreatmentGilles de la Tourette's Syndrome1
2Unknown StatusTreatmentGilles de la Tourette's Syndrome1
Not AvailableCompletedBasic ScienceAmyotrophic Lateral Sclerosis (ALS)1
Not AvailableCompletedTreatmentChronic Pelvic Pain / Endometriosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP5.74ALOGPS
logP4.98ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)15.46ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity90.09 m3·mol-1ChemAxon
Polarizability40.05 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0w29-7179000000-22766d934944105dccf9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-9130000000-c6d2bfc2e68da1f5b0d2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-9410000000-d078025cabaaf62c59b9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-1090000000-5224a67dd0daaea79191
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01ot-5090000000-dd9396934201d60f5af2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9010000000-d5bf936e945bfc965dfe

Drug created on May 22, 2018 11:59 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates